Intellipharmaceutics Announces First Quarter 2017 Results
11 avr. 2017 18h48 HE
|
Intellipharmaceutics International Inc.
TORONTO, April 11, 2017 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (NASDAQ:IPCI) (TSX:IPCI) (“Intellipharmaceutics” or the “Company”), a pharmaceutical company specializing in the...
Intellipharmaceutics Announces Patent Litigation by Purdue against its Rexista™ Abuse-Deterrent Extended-Release Oxycodone
10 avr. 2017 08h00 HE
|
Intellipharmaceutics International Inc.
TORONTO, April 10, 2017 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in...
Intellipharmaceutics Announces TSX Trading Symbol Change to “IPCI”
16 mars 2017 08h00 HE
|
Intellipharmaceutics International Inc.
TORONTO, March 16, 2017 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in...
Intellipharmaceutics Announces FDA Approval for 500 mg and 750 mg Generic Glucophage® XR
24 févr. 2017 08h00 HE
|
Intellipharmaceutics International Inc.
TORONTO, Feb. 24, 2017 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the...
Intellipharmaceutics Announces 2016 Year End Results
10 févr. 2017 08h00 HE
|
Intellipharmaceutics International Inc.
TORONTO, Feb. 10, 2017 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (NASDAQ:IPCI) (TSX:I) (“Intellipharmaceutics” or the “Company”), a pharmaceutical company specializing in the...
Intellipharmaceutics Announces FDA Acceptance for Filing of NDA for Rexista™ (oxycodone hydrochloride extended release), an Abuse Deterrent Opioid Analgesic for the Treatment of Moderate to Severe Pain
02 févr. 2017 17h00 HE
|
Intellipharmaceutics International Inc.
TORONTO, Feb. 02, 2017 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the...
Intellipharmaceutics Reports on Launch of Additional Strengths of Generic Focalin XR® by Par Pharmaceutical
06 janv. 2017 08h00 HE
|
Intellipharmaceutics International Inc.
TORONTO, Jan. 06, 2017 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing...
Intellipharmaceutics to Present at the Biotech Showcase™
29 déc. 2016 08h00 HE
|
Intellipharmaceutics International Inc.
TORONTO, Dec. 29, 2016 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the...
Intellipharmaceutics Announces Issuance of U.S. and Canadian Patents Covering Aspects of its PODRAS™ Overdose Technology
21 déc. 2016 08h00 HE
|
Intellipharmaceutics International Inc.
TORONTO, Dec. 21, 2016 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the...
Intellipharmaceutics to Present at the LD Micro Main Event
29 nov. 2016 08h00 HE
|
Intellipharmaceutics International Inc.
TORONTO, Nov. 29, 2016 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in...